Sodium-glucose cotransporter 1 (SGLT1) and SGLT2 inhibitors play protective roles in small vessel disease (SVD) via Cholesterol to oleoyl-linoleoyl-glycerol (18:1 to 18:2) [2] ratio (Lv et al., 2024b). This evidence concerns the gene SLC5A2 and snowflake vitreoretinal degeneration.